BioMarin Reaches New 52-Week High (BMRN)

NEW YORK ( TheStreet) -- BioMarin Pharmaceuticals (Nasdaq: BMRN) hit a new 52-week high Friday as it is currently trading at $39.39, above its previous 52-week high of $39.29 with 701,488 shares traded as of 12:05 p.m. ET. Average volume has been 1.4 million shares over the past 30 days.

BioMarin has a market cap of $4.41 billion and is part of the health care sector and drugs industry. Shares are up 9.5% year to date as of the close of trading on Thursday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world.

TheStreet Ratings rates BioMarin as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. You can view the full BioMarin Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Trump's FDA: A Friendlier Biotech Sheriff

Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run

Why I Hate the FAANGs (but Like Banks and Biotech) for 2017's Second Half

3 Fearless Predictions for the Second Half